BeiGene Announces New Chief Fiscal Officer, Julia Wang | Small business & Finance

Julia Wang, appointed Chief Monetary Officer of BeiGene, productive June 30, 2021 (Picture: Business Wire)

Ms. Wang has extensive world-wide finance experience across the biotech, pharmaceutical, health-related system, diagnostic, and buyer solutions industries. She joined BeiGene in June 2020 as Senior Vice President, Organization Optimization and Deputy CFO, primarily based in the Company’s Cambridge, MA business, and has been instrumental in driving worth generation by means of partnering throughout the firm and optimizing source allocation when elevating the leadership of the Finance function. In link with the CFO transition, Angus Grant, Ph.D., Main Company Executive, will oversee the Company’s strategy teams.

“Julia has experienced an critical influence and been an integral member of our govt group since joining BeiGene nearly a 12 months in the past. We are fortunate to have her deep expertise in foremost monetary functions as we become a bigger group with hundreds of colleagues and extensive functions all-around the world,” commented John V. Oyler, Co-Founder, Chief Government Officer, and Chairman of BeiGene. “We are grateful to have had Howard’s service due to the fact 2015, as a focused, insightful leader and close friend. We wish him the finest and thank him for his a lot of contributions, including the ongoing transition of his duties.”

“I am humbled by the prospect to provide as CFO of BeiGene, as we search to renovate the biotechnology field by producing impactful medicines that will be reasonably priced and obtainable to considerably much more patients close to the world,” commented Ms. Wang. “Our motivation to serve sufferers resonates through the corporation in the get the job done we do just about every day. I aim to build on the solid basis that Howard has recognized for BeiGene as a twin-mentioned, industrial-stage progress company, with assets that permit us to proceed to invest in our business enterprise as we endeavor to execute our crucial mission.”

Prior to becoming a member of BeiGene, Ms. Wang served as Senior Vice President, World wide Small business Finance and Company Scheduling at Alexion Prescription drugs. Prior to that she held management positions at Quest Diagnostics, including Vice President of U.S. Regional Finance and Company Business, and Vice President of Finance, Value Development. Right before Quest, Ms. Wang held senior leadership roles at Johnson & Johnson (J&J) as CFO of many functioning corporations, including Xian-Janssen, J&J’s pharmaceutical enterprise in China. Previously, she also led finance initiatives at PepsiCo.

Ms. Wang gained her MBA from Fuqua Faculty of Business at Duke College and her BA in British Language and Literature from Shandong Ordinary College.

BeiGene is a global, professional-phase biotechnology business centered on discovering, acquiring, production, and commercializing impressive medications to enhance remedy outcomes and entry for clients around the globe. Our 5,400+ staff close to the entire world are dedicated to expediting the advancement of a various pipeline of novel therapeutics. We currently market two internally discovered oncology medications: BTK inhibitor BRUKINSA ® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to sector supplemental oncology items in China licensed from Amgen Inc. Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) corporation and EUSA Pharma and have entered a collaboration with Novartis Pharma AG for Novartis to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan. To study much more about BeiGene, be sure to take a look at www.beigene.com and abide by us on Twitter at @BeiGeneUSA.

Ahead-Searching Statements

This push launch has ahead-hunting statements within just the meaning of the Personal Securities Litigation Reform Act of 1995 and other federal securities rules, which include statements regarding BeiGene’s capability and travel to deliver ground breaking medications extra affordably to sufferers around the entire world and have a sustained influence the biotechnology market. Actual final results may possibly differ materially from those people indicated in the forward-looking statements as a consequence of many significant variables, which includes BeiGene’s capacity to reveal the efficacy and safety of its drug candidates the medical outcomes for its drug candidates, which may possibly not help even more progress or marketing and advertising approval actions of regulatory organizations, which may perhaps affect the initiation, timing and development of medical trials and marketing and advertising acceptance BeiGene’s ability to reach industrial achievements for its marketed medicines and drug candidates, if accredited BeiGene’s capacity to acquire and preserve security of intellectual property for its medications and technological know-how BeiGene’s reliance on 3rd functions to perform drug development, manufacturing and other services BeiGene’s confined working experience in obtaining regulatory approvals and commercializing pharmaceutical solutions and its potential to receive more funding for functions and to finish the enhancement of its drug candidates and realize and sustain profitability the impact of the COVID-19 pandemic on the BeiGene’s scientific progress, regulatory, business, and other operations, as perfectly as individuals risks much more absolutely reviewed in the part entitled “Risk Factors” in BeiGene’s most the latest once-a-year report on Sort 10-K as nicely as conversations of likely pitfalls, uncertainties, and other significant things in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All facts in this press release is as of the date of this push release, and BeiGene undertakes no responsibility to update such information unless necessary by legislation.

Get hold of: Investor Get in touch with

+1 857-302-5663 or +1 857-302-7596

Key phrase: MASSACHUSETTS CHINA UNITED STATES NORTH The usa ASIA PACIFIC

Industry Key phrase: ONCOLOGY Wellness OTHER Health and fitness Medical TRIALS PHARMACEUTICAL BIOTECHNOLOGY

Copyright Business Wire 2021.

PUB: 03/30/2021 08:30 AM/DISC: 03/30/2021 08:30 AM